{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:40:13Z","timestamp":1790721613787,"version":"4.1.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12,1]]},"DOI":"10.1097\/qai.0b013e3181f9c0b6","type":"journal-article","created":{"date-parts":[[2010,11,2]],"date-time":"2010-11-02T01:48:55Z","timestamp":1288662535000},"page":"S37-S42","source":"Crossref","is-referenced-by-count":38,"title":["Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis"],"prefix":"10.1097","volume":"55","author":[{"given":"Gerald","family":"Friedland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-8-20210131","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update.","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"R4-8-20210131","first-page":"1","article-title":"Surveillance for acute viral hepatitis-United States, 2007.","volume":"58","author":"Daniels","year":"2009","journal-title":"MMWR Surveill Summ"},{"key":"R5-8-20210131","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.3748\/wjg.v13.i17.2436","article-title":"Epidemiology of hepatitis C virus infection.","volume":"13","author":"Alter","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R6-8-20210131","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1086\/588297","article-title":"Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.","volume":"46","author":"Amon","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R7-8-20210131","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00042560-200202010-00014","article-title":"High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China.","volume":"29","author":"Zhang","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R8-8-20210131","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0168-8278(99)80380-8","article-title":"Hepatitis C virus infection in Eastern Europe.","volume":"31","author":"Naoumov","year":"1999","journal-title":"J Hepatol"},{"key":"R9-8-20210131","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1177\/003335490612100611","article-title":"Self-reported hepatitis C virus antibody status and risk behavior in young injectors.","volume":"121","author":"Hagan","year":"2006","journal-title":"Public Health Rep"},{"issue":"Suppl 1","key":"R10-8-20210131","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1086\/429489","article-title":"Coinfection with HIV and hepatitis C virus in injection drug users and minority populations.","volume":"41","author":"Strader","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R12-8-20210131","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.","volume":"166","author":"Weber","year":"2006","journal-title":"Arch Intern Med"},{"key":"R13-8-20210131","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co infected patients. The Multivirc Group.","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"R14-8-20210131","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.288.2.199","article-title":"Hepatitis C and progression of HIV disease.","volume":"288","author":"Sulkowski","year":"2002","journal-title":"JAMA"},{"key":"R15-8-20210131","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11904-004-0019-6","article-title":"Hepatitis C virus infection in HIV-infected patients.","volume":"1","author":"Sulkowski","year":"2004","journal-title":"Curr HIV\/AIDS Rep"},{"key":"R16-8-20210131","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1468-1293.2006.00384.x","article-title":"Risk factors for fibrosis progression in HIV\/HCV co infected patients from a retrospective analysis of liver biopsies in 1985-2002.","volume":"7","author":"Schiavini","year":"2006","journal-title":"HIV Med"},{"key":"R17-8-20210131","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2893.2006.00816.x","article-title":"Therapeutic issues in HIV\/HCV-co infected patients.","volume":"14","author":"Sulkowski","year":"2007","journal-title":"J Viral Hepat"},{"key":"R18-8-20210131","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients co infected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"key":"R19-8-20210131","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1089\/apc.2009.0099","article-title":"Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population.","volume":"23","author":"Scott","year":"2009","journal-title":"AIDS Patient Care STDS"},{"key":"R20-8-20210131","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users.","volume":"33","author":"Mehta","year":"2008","journal-title":"J Community Health"},{"key":"R21-8-20210131","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jsat.2008.09.009","article-title":"Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.","volume":"37","author":"Litwin","year":"2009","journal-title":"J Subst Abuse Treat"},{"key":"R22-8-20210131","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.02.003","article-title":"Antiretroviral adherence and HIV treatment outcomes among HIV\/HCV co-infected injection drug users: the role of methadone maintenance therapy.","volume":"84","author":"Palepu","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"R23-8-20210131","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jsat.2010.02.002","article-title":"High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin.","volume":"38","author":"Waizmann","year":"2010","journal-title":"J Subst Abuse Treat"},{"key":"R24-8-20210131","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1086\/591707","article-title":"Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations.","volume":"47","author":"Maru","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R25-8-20210131","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJM200107193450311","article-title":"Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?","volume":"345","author":"Edlin","year":"2001","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"R27-8-20210131","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/518667","article-title":"Tuberculosis and HIV coinfection: current state of knowledge and research priorities.","volume":"196","author":"Friedland","year":"2007","journal-title":"J Infect Dis"},{"key":"R30-8-20210131","first-page":"1103","article-title":"Reported HIV Status of Tuberculosis Patients-United States, 1993-2005.","volume":"56","year":"2007","journal-title":"MMWR"},{"key":"R31-8-20210131","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/archinternmed.2008.535","article-title":"Tuberculosis and substance abuse in the United States, 1997-2006.","volume":"169","author":"Oeltmann","year":"2009","journal-title":"Arch Intern Med"},{"key":"R32-8-20210131","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM198903023200901","article-title":"A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection.","volume":"320","author":"Selwyn","year":"1989","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"R33-8-20210131","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1086\/651496","article-title":"Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts.","volume":"50","author":"Shenoi","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R36-8-20210131","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1164\/rccm.200907-0989OC","article-title":"HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality.","volume":"181","author":"Gandhi","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R37-8-20210131","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(06)69573-1","article-title":"Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.","volume":"368","author":"Gandhi","year":"2006","journal-title":"Lancet"},{"key":"R38-8-20210131","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11908-007-0039-7","article-title":"Tuberculosis, drug resistance, and HIV\/AIDS: a triple threat.","volume":"9","author":"Friedland","year":"2007","journal-title":"Curr Infect Dis Rep"},{"key":"R39-8-20210131","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/QAI.0b013e31818ce6c4","article-title":"Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonqoba study.","volume":"50","author":"Gandhi","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R40-8-20210131","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/00126334-200408010-00006","article-title":"A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting.","volume":"36","author":"Jack","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R41-8-20210131","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy.","volume":"362","author":"Abdool Karim","year":"2010","journal-title":"N Engl J Med"},{"key":"R42-8-20210131","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.qai.0000219769.89679.ec","article-title":"Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice.","volume":"41","author":"Bruce","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 4","key":"R43-8-20210131","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1086\/508186","article-title":"Pharmacokinetic interactions between buprenorphine and antiretroviral medications.","volume":"43","author":"Bruce","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R44-8-20210131","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1586\/17512433.1.1.115","article-title":"Pharmacokinetics drug interections between drugs of abuse and antiretroviral medications: implications and management for clinical practice.","volume":"1","author":"Bruce","year":"2008","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R47-8-20210131","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1521-0391.2009.00011.x","article-title":"Drug interactions of clinical importance with methadone and buprenorphine.","volume":"19","author":"McCance-Katz","year":"2010","journal-title":"Am J Addict"},{"key":"R48-8-20210131","first-page":"185","article-title":"Centers of Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep. 2000.","volume":"49","year":"2000","journal-title":"Available at:"},{"key":"R49-8-20210131","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJM197605132942008","article-title":"Rifampin-induced methadone withdrawal.","volume":"294","author":"Kreek","year":"1976","journal-title":"N Engl J Med"},{"key":"R50-8-20210131","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jac\/dkl399","article-title":"Administration of efavirenz (600 mg\/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.","volume":"58","author":"Friedland","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"R53-8-20210131","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.drugpo.2007.03.001","article-title":"Integration and co-location of HIV\/AIDS, tuberculosis and drug treatment services.","volume":"18","author":"Sylla","year":"2007","journal-title":"Int J Drug Policy"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-201012011-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:36:08Z","timestamp":1786041368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-201012011-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,1]]},"references-count":41,"journal-issue":{"issue":"Supplement 1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181f9c0b6","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12,1]]}}}